Shunjie Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Shunjie Chen has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
- Zhixiang Bian
Shanghai Fourth People's Hospital
4 shared publications Huaiji Wang
Department of Nephrology, Shanghai Fourth People's Hospital, School of Medicine, Tongji University, Shanghai, People's Republic of China
3 shared publicationsChenghao Wu
Department of Obstetrics and Gynecology, Tongji Hospital, Tongji University School of Medicine, No.389 Xincun Road, Shanghai 200065, People's Republic of China
2 shared publicationsMing Yang
Department of Nephrology, Shanghai Fourth People’s Hospital, School of Medicine, Tongji University, Shanghai, China
2 shared publicationsRui Zhu
Shanghai Fourth People's Hospital
2 shared publications- Rui Zhu
Department of Nephrology Shanghai Fourth People's Hospital School of Medicine Tongji University, Shanghai 200434, China
2 shared publications
Latest Publications
- 19 May 2026
- Published by SAGE Publications in Journal of the Renin-Angiotensin-Aldosterone System
- Vol. 27
Exosomal lncRNA-PVT1 secreted from bone marrow mesenchymal stem cells attenuates diabetic nephropathy by targeting miR-423-5p/Sirt1/HIF-1α signaling
Introduction: Diabetic nephropathy (DN) is a major cause of end-stage renal disease (ESRD), yet effective disease-modifying therapies remain limited. Emerging evidence implicates long non-coding RNAs (lncRNAs) in the pathogenesis of DN, but the functional relevance of plasmacytoma variant translocation 1 (PVT1) and its downstream mechanism remain poorly defined. Here, we investigated whether PVT1 protects against diabetic renal injury through the miR-423-5p/Sirt1/HIF-1α axis. Materials and Methods: DN was modeled in db/db mice and high glucose-treated renal cells. PVT1 was overexpressed or inhibited, and miR-423-5p was modulated using specific mimics or inhibitors. Renal function, histopathology, and fibrotic changes were evaluated by biochemical assays, histological staining, qRT-PCR, and Western blotting. The expression of PVT1, miR-423-5p, Sirt1, HIF-1α, and fibrosis-related markers was determined to define their regulatory relationships. Results: PVT1 was dysregulated in diabetic kidneys and high glucose-exposed renal cells. In db/db mice, PVT1 overexpression significantly improved renal function, as evidenced by reduced 24-h urinary protein excretion, serum creatinine, and blood urea nitrogen, and attenuated pathological renal injury. PVT1 also suppressed extracellular matrix accumulation and fibrosis-related signaling, including α-SMA, collagen I, collagen IV, fibronectin, and TGF-β1. Mechanistically, PVT1 acted through the miR-423-5p/Sirt1/HIF-1α pathway, and inhibition of miR-423-5p abrogated the renoprotective effects of PVT1. These findings support a functional model in which PVT1 alleviates diabetic renal injury by repressing miR-423-5p and restoring Sirt1-dependent signaling. Conclusions: PVT1 mitigates DN progression by targeting the miR-423-5p/Sirt1/HIF-1α axis and limiting renal fibrosis. This lncRNA-centered regulatory pathway may represent a promising therapeutic target for diabetic kidney disease.
- 19 May 2026
- Published by SAGE Publications in Journal of the Renin-Angiotensin-Aldosterone System
- Vol. 27
Exosomal lncRNA-PVT1 secreted from bone marrow mesenchymal stem cells attenuates diabetic nephropathy by targeting miR-423-5p/Sirt1/HIF-1α signaling
Introduction: Diabetic nephropathy (DN) is a major cause of end-stage renal disease (ESRD), yet effective disease-modifying therapies remain limited. Emerging evidence implicates long non-coding RNAs (lncRNAs) in the pathogenesis of DN, but the functional relevance of plasmacytoma variant translocation 1 (PVT1) and its downstream mechanism remain poorly defined. Here, we investigated whether PVT1 protects against diabetic renal injury through the miR-423-5p/Sirt1/HIF-1α axis. Materials and Methods: DN was modeled in db/db mice and high glucose-treated renal cells. PVT1 was overexpressed or inhibited, and miR-423-5p was modulated using specific mimics or inhibitors. Renal function, histopathology, and fibrotic changes were evaluated by biochemical assays, histological staining, qRT-PCR, and Western blotting. The expression of PVT1, miR-423-5p, Sirt1, HIF-1α, and fibrosis-related markers was determined to define their regulatory relationships. Results: PVT1 was dysregulated in diabetic kidneys and high glucose-exposed renal cells. In db/db mice, PVT1 overexpression significantly improved renal function, as evidenced by reduced 24-h urinary protein excretion, serum creatinine, and blood urea nitrogen, and attenuated pathological renal injury. PVT1 also suppressed extracellular matrix accumulation and fibrosis-related signaling, including α-SMA, collagen I, collagen IV, fibronectin, and TGF-β1. Mechanistically, PVT1 acted through the miR-423-5p/Sirt1/HIF-1α pathway, and inhibition of miR-423-5p abrogated the renoprotective effects of PVT1. These findings support a functional model in which PVT1 alleviates diabetic renal injury by repressing miR-423-5p and restoring Sirt1-dependent signaling. Conclusions: PVT1 mitigates DN progression by targeting the miR-423-5p/Sirt1/HIF-1α axis and limiting renal fibrosis. This lncRNA-centered regulatory pathway may represent a promising therapeutic target for diabetic kidney disease.
- Open Access
- 1 January 2026
- Published by Wiley in Advances in Urology
- Vol. 2026 (1) , 9179415
Klotho G‐395A Polymorphism as a Risk Factor for Atrial Fibrillation in Patients on Maintenance Hemodialysis
Objective: To explore the relationship between atrial fibrillation and the Klotho G‐395A polymorphism in patients on maintenance hemodialysis (MHD). Methods: The study included 120 MHD patients (persistent atrial fibrillation, n = 30; paroxysmal atrial fibrillation, n = 30; normal sinus rhythm, n = 60) and 120 control individuals. Klotho G‐395A mutations were detected by the fluorescence quantitative polymerase chain reaction. ELISA was used to detect serum soluble Klotho (sKl) and intact fibroblast growth factor 23 (iFGF23) levels, and left atrium diameters were measured by echocardiography. Correlation analysis between Klotho G‐395A genotypes, clinical parameters, and biochemical indexes was performed, along with logistic regression analysis to determine the risk factors for atrial fibrillation. Results: Three genotypes of Klotho G‐395A, namely, GG, GA, and AA, were detected. The frequencies of the GA/AA genotypes and A allelic genes were significantly higher in the MHD patients than in the healthy controls, and these genotypes were associated with both atrial fibrillation and persistent atrial fibrillation. Furthermore, serum sKl, serum iFGF23, and left artery diameter were significantly associated with atrial fibrillation and also showed significant differences between the persistent and paroxysmal atrial fibrillation groups. The serum sKl level was negatively correlated with serum FGF23 level and the left atrium diameter, while the serum FGF23 level was positively correlated with the left atrium diameter. The incidence of atrial fibrillation and left atrium diameter was significantly higher in those with the GA/AA genotype than in those with the GG genotype, while the serum sKl levels were significantly lower. The GA/AA genotype was associated with a 5.444 times higher likelihood of atrial fibrillation than the GG genotype. Conclusions: The A allele of Klotho G‐395A may be a risk marker of atrial fibrillation in MHD patients. Moreover, sKl deficiency may contribute to the early development of atrial fibrillation in MHD patients.
- 1 January 2026
- Published by Wiley in Advances in Urology
- Vol. 2026 (1) , 9179415
Open AccessKlotho G‐395A Polymorphism as a Risk Factor for Atrial Fibrillation in Patients on Maintenance Hemodialysis
Objective: To explore the relationship between atrial fibrillation and the Klotho G‐395A polymorphism in patients on maintenance hemodialysis (MHD). Methods: The study included 120 MHD patients (persistent atrial fibrillation, n = 30; paroxysmal atrial fibrillation, n = 30; normal sinus rhythm, n = 60) and 120 control individuals. Klotho G‐395A mutations were detected by the fluorescence quantitative polymerase chain reaction. ELISA was used to detect serum soluble Klotho (sKl) and intact fibroblast growth factor 23 (iFGF23) levels, and left atrium diameters were measured by echocardiography. Correlation analysis between Klotho G‐395A genotypes, clinical parameters, and biochemical indexes was performed, along with logistic regression analysis to determine the risk factors for atrial fibrillation. Results: Three genotypes of Klotho G‐395A, namely, GG, GA, and AA, were detected. The frequencies of the GA/AA genotypes and A allelic genes were significantly higher in the MHD patients than in the healthy controls, and these genotypes were associated with both atrial fibrillation and persistent atrial fibrillation. Furthermore, serum sKl, serum iFGF23, and left artery diameter were significantly associated with atrial fibrillation and also showed significant differences between the persistent and paroxysmal atrial fibrillation groups. The serum sKl level was negatively correlated with serum FGF23 level and the left atrium diameter, while the serum FGF23 level was positively correlated with the left atrium diameter. The incidence of atrial fibrillation and left atrium diameter was significantly higher in those with the GA/AA genotype than in those with the GG genotype, while the serum sKl levels were significantly lower. The GA/AA genotype was associated with a 5.444 times higher likelihood of atrial fibrillation than the GG genotype. Conclusions: The A allele of Klotho G‐395A may be a risk marker of atrial fibrillation in MHD patients. Moreover, sKl deficiency may contribute to the early development of atrial fibrillation in MHD patients.
- Open Access
- 1 January 2026
- Published by Wiley in Advances in Urology
- Vol. 2026 (1)
Prognostic Value of Serum Cystatin C for Predicting Contrast‐Induced Nephropathy in Elderly Individuals Aged Over 80 Years
Objective: To explore the predictive value of serum cystatin C (CysC) for contrast‐induced acute kidney injury (CI‐AKI) in elderly individuals. Methods: The study included 102 elderly patients (80 years) who underwent percutaneous coronary interventions at the Fourth People’s Hospital of Shanghai Affiliated to Tongji University between September 2020 and January 2024. Based on their diagnosis, they were divided into those with CI‐AKI ( n = 10) and those without CI‐AKI ( n = 92). A fully automated biochemical analyzer was used to measure the serum CysC levels at baseline and 48 h after coronary angiography or percutaneous coronary intervention in the two groups, and the association of serum CysC levels and other relevant clinical indicators with the occurrence of CI‐AKI was evaluated to determine the predictive value of baseline serum CysC for diagnosing contrast agent‐induced nephropathy based on receiver operating characteristic curves. Results: Age, serum CysC, and serum creatinine levels were significantly higher in the CI‐AKI group than in the non‐CI‐AKI group. Serum CysC was found to be a predictor of CI‐AKI based on an area under the curve of 0.731 (95% confidence interval = 0.569–0.893). Conclusion: The occurrence of contrast‐induced nephropathy is related to age, serum CysC, and serum creatinine levels. In particular, serum CysC had high predictive value for CI‐AKI in those aged above 80 years.
- 1 January 2026
- Published by Wiley in Advances in Urology
- Vol. 2026 (1)
Open AccessPrognostic Value of Serum Cystatin C for Predicting Contrast‐Induced Nephropathy in Elderly Individuals Aged Over 80 Years
Objective: To explore the predictive value of serum cystatin C (CysC) for contrast‐induced acute kidney injury (CI‐AKI) in elderly individuals. Methods: The study included 102 elderly patients (80 years) who underwent percutaneous coronary interventions at the Fourth People’s Hospital of Shanghai Affiliated to Tongji University between September 2020 and January 2024. Based on their diagnosis, they were divided into those with CI‐AKI ( n = 10) and those without CI‐AKI ( n = 92). A fully automated biochemical analyzer was used to measure the serum CysC levels at baseline and 48 h after coronary angiography or percutaneous coronary intervention in the two groups, and the association of serum CysC levels and other relevant clinical indicators with the occurrence of CI‐AKI was evaluated to determine the predictive value of baseline serum CysC for diagnosing contrast agent‐induced nephropathy based on receiver operating characteristic curves. Results: Age, serum CysC, and serum creatinine levels were significantly higher in the CI‐AKI group than in the non‐CI‐AKI group. Serum CysC was found to be a predictor of CI‐AKI based on an area under the curve of 0.731 (95% confidence interval = 0.569–0.893). Conclusion: The occurrence of contrast‐induced nephropathy is related to age, serum CysC, and serum creatinine levels. In particular, serum CysC had high predictive value for CI‐AKI in those aged above 80 years.
- 17 August 2024
- Published by Elsevier in The American Journal of the Medical Sciences
- Vol. 368 (6) , 660-667
Epidural block with lidocaine ameliorates kidney function deterioration and fibrosis of chronic kidney disease in rats
- 17 August 2024
- Published by Elsevier in The American Journal of the Medical Sciences
- Vol. 368 (6) , 660-667
Epidural block with lidocaine ameliorates kidney function deterioration and fibrosis of chronic kidney disease in rats
- Open Access
- 1 January 2024
- Published by Wiley in Advances in Urology
- Vol. 2024 (1) , 6456411
A Review of Electronic Early Warning Systems for Acute Kidney Injury
Acute kidney injury (AKI) is characterized by impaired renal function that can result in irreversible severe renal impairment or lifelong dependence on renal replacement therapy in some cases. Early intervention can significantly slow down the progression of AKI and reduce mortality. In recent years, electronic early warning systems for patients with AKI have been gaining attention as a potential clinical decision‐support option. This paper presents a review of the application of electronic early warning systems for AKI from four aspects: development process, types of output, influencing factors, and system evaluation.
- 1 January 2024
- Published by Wiley in Advances in Urology
- Vol. 2024 (1) , 6456411
Open AccessA Review of Electronic Early Warning Systems for Acute Kidney Injury
Acute kidney injury (AKI) is characterized by impaired renal function that can result in irreversible severe renal impairment or lifelong dependence on renal replacement therapy in some cases. Early intervention can significantly slow down the progression of AKI and reduce mortality. In recent years, electronic early warning systems for patients with AKI have been gaining attention as a potential clinical decision‐support option. This paper presents a review of the application of electronic early warning systems for AKI from four aspects: development process, types of output, influencing factors, and system evaluation.
- Open Access
- 1 January 2024
- Published by S. Karger AG in Kidney and Blood Pressure Research
- Vol. 49 (1) , 60-68
Inflammation Is More Sensitive than Cell Proliferation in Response to Rapamycin Treatment in Polycystic Kidney Disease
Introduction: It has been reported that rapamycin inhibited inflammation in renal interstitial diseases. We therefore hypothesized that rapamycin could attenuate inflammation in polycystic kidney disease (PKD). Methods: Han:SPRD rats were treated with rapamycin by daily gavage from 4 weeks to 12 weeks of age at the dosage of 0.5 mg/kg/day (low dose) or 1 mg/kg/day (high dose). WT9-12 human PKD cells were treated with various concentrations of rapamycin. Results: Two-kidney/total body weight ratio and cystic index in Cy/+ kidneys were significantly reduced with the treatment of low-dose rapamycin and further reduced by the treatment with high-dose rapamycin. However, the renal function of Cy/+ rats was equally improved by the treatment with either low-dose or high-dose rapamycin. The renal cell proliferation was significantly decreased in Cy/+ kidneys with the treatment of low-dose rapamycin and was further decreased with the treatment of high-dose rapamycin as examined by Ki67 staining. The phosphorylation of S6K in cystic kidneys was decreased by low-dose rapamycin and further decreased by high-dose rapamycin. Both low-dose and high-dose rapamycin treatment decreased macrophage infiltration and the expression of complement factor B (CFB), monocyte chemoattractant protein-1 (MCP-1), and tumor necrosis factor-alpha (TNF-α) to a similar level. The expression of CFB, MCP-1, and TNF-α and phosphorylation of S6K were inhibited in WT9-12 cells treated with 10 nm rapamycin at 24 h and 48 h, respectively. Moreover, the phosphorylation of Akt was not increased by 1 nm and 10 nm of rapamycin and enhanced by 1 μm rapamycin treatment. Interestingly, WT9-12 cell proliferation could be inhibited by 1 μm rapamycin. Conclusion: Low dose of rapamycin could inhibit inflammation and protect renal function in PKD. Inflammation is more sensitive than cell proliferation in response to rapamycin treatment in PKD.
- 1 January 2024
- Published by S. Karger AG in Kidney and Blood Pressure Research
- Vol. 49 (1) , 60-68
Open AccessInflammation Is More Sensitive than Cell Proliferation in Response to Rapamycin Treatment in Polycystic Kidney Disease
Introduction: It has been reported that rapamycin inhibited inflammation in renal interstitial diseases. We therefore hypothesized that rapamycin could attenuate inflammation in polycystic kidney disease (PKD). Methods: Han:SPRD rats were treated with rapamycin by daily gavage from 4 weeks to 12 weeks of age at the dosage of 0.5 mg/kg/day (low dose) or 1 mg/kg/day (high dose). WT9-12 human PKD cells were treated with various concentrations of rapamycin. Results: Two-kidney/total body weight ratio and cystic index in Cy/+ kidneys were significantly reduced with the treatment of low-dose rapamycin and further reduced by the treatment with high-dose rapamycin. However, the renal function of Cy/+ rats was equally improved by the treatment with either low-dose or high-dose rapamycin. The renal cell proliferation was significantly decreased in Cy/+ kidneys with the treatment of low-dose rapamycin and was further decreased with the treatment of high-dose rapamycin as examined by Ki67 staining. The phosphorylation of S6K in cystic kidneys was decreased by low-dose rapamycin and further decreased by high-dose rapamycin. Both low-dose and high-dose rapamycin treatment decreased macrophage infiltration and the expression of complement factor B (CFB), monocyte chemoattractant protein-1 (MCP-1), and tumor necrosis factor-alpha (TNF-α) to a similar level. The expression of CFB, MCP-1, and TNF-α and phosphorylation of S6K were inhibited in WT9-12 cells treated with 10 nm rapamycin at 24 h and 48 h, respectively. Moreover, the phosphorylation of Akt was not increased by 1 nm and 10 nm of rapamycin and enhanced by 1 μm rapamycin treatment. Interestingly, WT9-12 cell proliferation could be inhibited by 1 μm rapamycin. Conclusion: Low dose of rapamycin could inhibit inflammation and protect renal function in PKD. Inflammation is more sensitive than cell proliferation in response to rapamycin treatment in PKD.
- Open Access
- 24 November 2023
- Published by Frontiers Media SA in Frontiers in Genetics
- Vol. 14, 1159868
In-depth exploration of the shared genetic signature and molecular mechanisms between end-stage renal disease and osteoporosis
Background: Osteoporosis (OS) and fractures are common in patients with end-stage renal disease (ESRD) and maintenance dialysis patients. However, diagnosing osteoporosis in this population is challenging. The aim of this research is to explore the common genetic profile and potential molecular mechanisms of ESRD and OS.Methods and results: Download microarray data for ESRD and OS from the Gene Expression Omnibus (GEO) database. Weighted correlation network analysis (WGCNA) was used to identify co-expression modules associated with ESRD and OS. Random Forest (RF) and Lasso Regression were performed to identify candidate genes, and consensus clustering for hierarchical analysis. In addition, miRNAs shared in ESRD and OS were identified by differential analysis and their target genes were predicted by Tragetscan. Finally, we constructed a common miRNAs-mRNAs network with candidate genes and shared miRNAs. By WGCNA, two important modules of ESRD and one important module of OS were identified, and the functions of three major clusters were identified, including ribosome, RAS pathway, and MAPK pathway. Eight gene signatures obtained by using RF and Lasso machine learning methods with area under curve (AUC) values greater than 0.7 in ESRD and in OS confirmed their diagnostic performance. Consensus clustering successfully stratified ESRD patients, and C1 patients with more severe ESRD phenotype and OS phenotype were defined as “OS-prone group”.Conclusion: Our work identifies biological processes and underlying mechanisms shared by ESRD and OS, and identifies new candidate genes that can be used as biomarkers or potential therapeutic targets, revealing molecular alterations in susceptibility to OS in ESRD patients.
- 24 November 2023
- Published by Frontiers Media SA in Frontiers in Genetics
- Vol. 14, 1159868
Open AccessIn-depth exploration of the shared genetic signature and molecular mechanisms between end-stage renal disease and osteoporosis
Background: Osteoporosis (OS) and fractures are common in patients with end-stage renal disease (ESRD) and maintenance dialysis patients. However, diagnosing osteoporosis in this population is challenging. The aim of this research is to explore the common genetic profile and potential molecular mechanisms of ESRD and OS.Methods and results: Download microarray data for ESRD and OS from the Gene Expression Omnibus (GEO) database. Weighted correlation network analysis (WGCNA) was used to identify co-expression modules associated with ESRD and OS. Random Forest (RF) and Lasso Regression were performed to identify candidate genes, and consensus clustering for hierarchical analysis. In addition, miRNAs shared in ESRD and OS were identified by differential analysis and their target genes were predicted by Tragetscan. Finally, we constructed a common miRNAs-mRNAs network with candidate genes and shared miRNAs. By WGCNA, two important modules of ESRD and one important module of OS were identified, and the functions of three major clusters were identified, including ribosome, RAS pathway, and MAPK pathway. Eight gene signatures obtained by using RF and Lasso machine learning methods with area under curve (AUC) values greater than 0.7 in ESRD and in OS confirmed their diagnostic performance. Consensus clustering successfully stratified ESRD patients, and C1 patients with more severe ESRD phenotype and OS phenotype were defined as “OS-prone group”.Conclusion: Our work identifies biological processes and underlying mechanisms shared by ESRD and OS, and identifies new candidate genes that can be used as biomarkers or potential therapeutic targets, revealing molecular alterations in susceptibility to OS in ESRD patients.
- 15 December 2022
- Published by Elsevier in Journal of Controlled Release
- Vol. 353, 727-737
A Biomimetic Metal-Organic Framework Nanosystem Modulates Immunosuppressive Tumor Microenvironment Metabolism to Amplify Immunotherapy
- 15 December 2022
- Published by Elsevier in Journal of Controlled Release
- Vol. 353, 727-737
A Biomimetic Metal-Organic Framework Nanosystem Modulates Immunosuppressive Tumor Microenvironment Metabolism to Amplify Immunotherapy
- Open Access
- 1 September 2022
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 17, 3841-3851
Microneedle Patch Delivery of Methotrexate-Loaded Albumin Nanoparticles to Immune Cells Achieves a Potent Antipsoriatic Effect
Introduction: Transdermal drug delivery provides a desirable alternative method of penetrating the skin for psoriasis treatment, by virtue of its ability to dampen the overactivation of immune cells and inflammation, while attenuating the detrimental effects of systemic administration. Lymph nodes (LNs), as a critical organ of the lymphatic and the acquired immune system, are suitable sites for drug homing to suppress the immune cells. Methods: In this context, we developed a microneedle (MN) patch that delivers nanodrugs locally to LNs for improving the antipsoriatic treatment. In this study, human serum albumin nanoparticles carrying methotrexate (HM) were synthesized and loaded into hyaluronic acid (HA)-based microneedles (HM/MN). Results: The patch showed an excellent ability to pierce the skin, which enhanced drug delivery. In a mouse model of psoriasis, the HM/MN patch significantly prevented the erythema with decreased skin thickness, thus inhibiting the progression of psoriasis. Further analysis for immune cells in LNs, the percent of dendritic cells (DC) and T cells reduced after the local treatment with HM/MN. Notably, the feasibility of targeted delivery of methotrexate to LNs using nanoparticles was verified by detecting increased accumulation of methotrexate in LNs. In addition, the HM/MN patch pronouncedly decreased the levels of tumor necrosis factor α and interleukin 6 in the skin. Conclusion: The results suggested the high efficacy of using the HM/MN patch to treat psoriasis, and provided new insight into the mechanism of the transdermal drug delivery system.
- 1 September 2022
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 17, 3841-3851
Open AccessMicroneedle Patch Delivery of Methotrexate-Loaded Albumin Nanoparticles to Immune Cells Achieves a Potent Antipsoriatic Effect
Introduction: Transdermal drug delivery provides a desirable alternative method of penetrating the skin for psoriasis treatment, by virtue of its ability to dampen the overactivation of immune cells and inflammation, while attenuating the detrimental effects of systemic administration. Lymph nodes (LNs), as a critical organ of the lymphatic and the acquired immune system, are suitable sites for drug homing to suppress the immune cells. Methods: In this context, we developed a microneedle (MN) patch that delivers nanodrugs locally to LNs for improving the antipsoriatic treatment. In this study, human serum albumin nanoparticles carrying methotrexate (HM) were synthesized and loaded into hyaluronic acid (HA)-based microneedles (HM/MN). Results: The patch showed an excellent ability to pierce the skin, which enhanced drug delivery. In a mouse model of psoriasis, the HM/MN patch significantly prevented the erythema with decreased skin thickness, thus inhibiting the progression of psoriasis. Further analysis for immune cells in LNs, the percent of dendritic cells (DC) and T cells reduced after the local treatment with HM/MN. Notably, the feasibility of targeted delivery of methotrexate to LNs using nanoparticles was verified by detecting increased accumulation of methotrexate in LNs. In addition, the HM/MN patch pronouncedly decreased the levels of tumor necrosis factor α and interleukin 6 in the skin. Conclusion: The results suggested the high efficacy of using the HM/MN patch to treat psoriasis, and provided new insight into the mechanism of the transdermal drug delivery system.